Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy.
Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Garber J, Merajver S, Balmanya J, Meirovitz A, Domchek S. Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy. Cancer Research 2009, 69: 959-959. DOI: 10.1158/0008-5472.sabcs-09-959.Peer-Reviewed Original ResearchContralateral breast cancerOperable breast cancerBreast conservationBreast cancerLocal therapyBRCA1/2 mutationsDistant failureClinical characteristicsBRCA1/2 carriersLocal failureBC-specific survivalDeleterious BRCA1/2 mutationsLocal treatment optionsInvasive lobular cancerGermline BRCA1/2 mutationsSignificant predictorsSignificant differencesOnly significant predictorAdjuvant chemotherapyBCT patientsOverall survivalContralateral breastLobular cancerLocal recurrenceRandomized trialsBreast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups
Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Annals Of Oncology 2009, 20: 1653-1659. PMID: 19491284, DOI: 10.1093/annonc/mdp051.Peer-Reviewed Original ResearchConceptsBreast cancerSecondary malignanciesAge of onsetFamily historyBRCA1/2 mutationsYoung womenBRCA1/2 mutation statusBreast cancer diagnosisEligible womenSecond cancersInitial diagnosisBRCA1/2 statusMutation statusBRCA1/2 genesYounger ageKorean womenCancerMalignancyUncertain significanceCancer diagnosisCaucasiansWomenDiverse racial groupsFrequent mutationsSignificant differences